ClinicalTrials.gg
CompletedNCT01457547Updated Aug 5, 2016

Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course

A Phase 4 interventional study of DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and DTPa-HBV-IPV-Hib vaccine (HEXAVAC™) in Hepatitis B, Poliomyelitis and Diphtheria, sponsored by GlaxoSmithKline. Completed at 9 sites in 3 countries. Open to participants aged 8 Weeks to 15 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-05.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
494
Allocation
Randomized
Ages
8 Weeks to 15 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Hepatitis B.

Enrollment
6th of 16
494 · median 417
Started
2003
the only one that year
Phase 4
6 of 16
none open now
Registered
9th of 16
by date
Lead sponsor
14 of 16
GlaxoSmithKline

Among the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B, this one is the 6th largest by enrollment, is the only one that started in 2003, is one of 6 in phase 4, and was the 9th registered.

Hepatitis B

1,048 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

None of the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B is open now. The open studies under Hepatitis B, anywhere →

About diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 8 Weeks to 15 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B as a file.
02

Study summary

The study will compare the immunogenicity and the reactogenicity of INFANRIX™ HEXA and HEXAVAC™ vaccines in a 3, 5 and 11 - 12 month vaccination schedule.

03

Conditions studied

  • Hepatitis B
  • Poliomyelitis
  • Diphtheria
  • Acellular Pertussis
  • Tetanus
  • Haemophilus Influenzae Type b

Keywords

  • HEXAVACTM
  • InfanrixTM HEXA
  • DTPa-HBV-IPV-Hib
  • DTPa-HBV-IPV/Hib
04

Who can participate

Ages eligible
8 Weeks to 15 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A healthy male or female subject between 8 and 15 weeks of age at the time of the first vaccination.
  • Written obtained from the parent or guardian of the subject prior to the study entry.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Born after a normal gestation period between 36 and 42 weeks.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered drug or vaccine other than the study vaccine within 30 days preceding the administration of the study vaccine, or planned use during the study period.
  • Evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, and/or Hib vaccination or disease.
  • Planned administration of a vaccine not foreseen by the study protocol since birth and during the period starting 30 days before the administration of the first dose and ending 30 days after the last dose of the three-dose primary vaccination course, with the exception of licensed Neisseria meningitides conjugate vaccines or Bacillus Calmette-Guérin (BCG) vaccine that can be given in between study visits or after the third visit, provided they are given preferably with a 4 weeks interval but not less than 3 weeks apart from the study vaccine doses.
  • Chronic administration or planned administration of immuno-suppressants or other immune-modifying drugs since birth.
  • Planned administration of immunoglobulins and/or any blood products since birth or planned administration during the period up to 30 days after the third dose of the primary vaccination course.
  • Any confirmed or suspected or immunodeficient condition, including (HIV) infection.
  • History of seizures, progressive neurological disease or intra-cerebral haemorrhage.
  • Major congenital defects or serious chronic illness.
  • Acute febrile illness at the time of planned vaccination
  • History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
494 participants (actual)

Study arms

  • Experimental
    DTPa 1 Group

    Biological: DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)

  • Active comparator
    DTPa 2 Group

    Biological: DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)

Interventions

06

What researchers measure

Primary outcomes

  1. Immunogenicity with respect to the components of the study vaccine in terms of antibody concentrations

    Time frame: Prior to the third primary vaccination dose ( Months 8-9)

Secondary outcomes

  1. Immunogenicity with respect to the components of the study vaccine in terms of antibody concentrations

    Time frame: One month after the second and third primary vaccination dose (Month 3 and Months 9-10)

  2. Immunogenicity with respect to the components of the study vaccine in terms of number of seroprotected subjects defined by antibody concentration

    Time frame: Prior to and one month after the third primary vaccination dose ( Months 8-9 and Months 9-10)

  3. Immunogenicity with respect to the components of the study vaccine in terms of number of seropositive subjects

    Time frame: Prior to and one month after the third primary vaccination dose ( Months 8-9 and Months 9-10)

  4. Occurrence of solicited symptoms

    Time frame: Within 4 days (Day 0 -Day 3) after each vaccine dose

  5. Occurrence of a grade "3" solicited symptoms

    Time frame: Within 4 days (Day 0 -Day 3) after each vaccine dose

  6. Occurrence of unsolicited adverse events

    Time frame: Within 31 days after any vaccination

  7. Occurrence of Serious Adverse Events

    Time frame: Throughout the entire study up to (Month 0 to Month 9-10) and including 30 days after last vaccination (Month 9-10)

07

Study locations

9 sites
  • GSK Investigational Site
    Helsinki, 00300, Finland
  • GSK Investigational Site
    Bologna, Emilia-Romagna 40138, Italy
  • GSK Investigational Site
    Pavia, Lombardia 27100, Italy
  • GSK Investigational Site
    Bari, Puglia 70124, Italy
  • GSK Investigational Site
    Galatina (LE), Puglia 73013, Italy
  • GSK Investigational Site
    Maglie (LE), Puglia 73024, Italy
  • GSK Investigational Site
    Sassari, Sardegna 07100, Italy
  • GSK Investigational Site
    Linköping, SE-581 85, Sweden
  • GSK Investigational Site
    Örebro, SE-701 85, Sweden
08

References and documents

Publications

  • Kilpi et al. Comparison of the immunogenicity and reactogenicity of two hexavalent DTPa-HBV-IPV/Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Abstract presented at the 24th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), Basel Switzerland 03-05 May, 2006.
  • Kilpi TM, Silfverdal SA, Nilsson L, Syrjanen R, Belloni C, Desole M, Triban C, Storsaeter J, Soila M, Jacquet JM. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Hum Vaccin. 2009 Jan-Feb;5(1):18-25. doi: 10.4161/hv.5.1.6369. Epub 2009 Jan 2. PubMed 18690013 ↗
  • Van Der Meeren O, Kuriyakose S, Kolhe D, Hardt K. Immunogenicity of Infanrix hexa administered at 3, 5 and 11 months of age. Vaccine. 2012 Apr 5;30(17):2710-4. doi: 10.1016/j.vaccine.2012.02.024. Epub 2012 Feb 18. PubMed 22349525 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003, a primary completion of May 2005 and a completion of May 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2011
First posted
Oct 24, 2011
Start
Oct 2003
Primary completionActual
May 2005
CompletionActual
May 2005
Last update
Aug 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01457547
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 24, 2011
Start date
Oct 2003
Primary completion
May 2005
Completion
May 2005
Last update
Aug 5, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion